Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco-25-00179 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Nadine Houédé und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, CHU Nîmes, Nîmes, France. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Urologic Neoplasms, Ureteral Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
PURPOSE After radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients. PATIENTS AND METHODS This phase II trial (ClinicalTrials.gov identifier: NCT04617756 ) included patients with nonmetastatic, high-grade UTUC, on the basis of the ureteroscopic biopsy or urine cytology, and/or infiltrative aspect of the renal pelvis/ureteral wall by computed tomography imaging. Before RNU, patients received durvalumab plus gemcitabine/cisplatin (cohort 1) or durvalumab plus gemcitabine/carboplatin (cohort 2) once every 3 weeks for a total of four cycles (cohort choice on the basis of the glomerular filtration rate). The primary objective was the pathologic complete response (ypT0) rate in each cohort. RESULTS Fifty patients were enrolled between 2021 and 2024 (31 in cohort 1; 19 in cohort 2). Median age was 68 years (range, 38-79), and 59% were men. Forty-five patients received four cycles of treatment, three patients three cycles, and one patient two cycles. Five patients switched to carboplatin during treatment. At surgery (N = 45 patients), rates of pT0 were 13% (4/29) in cohort 1 and 5% (1/19) in cohort 2. Fifty percent (15/29) of patients were pTa/pT1 in cohort 1, and 42% (8/19) in cohort 2. No severe immunotherapy-mediated toxicity was observed. Four patients had chemotherapy-related grade 3 neutropenia, one grade 4; one patient had grade 3 thrombopenia, one grade 4; and four patients had grade 3 anemia. CONCLUSION Although our negative study did not meet its primary end point in either cohort, the combination of durvalumab and platin-based chemotherapy, especially cisplatin, showed promising results in terms of downstaging. The safety profile was good and the surgical risk was not increased.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, CHU Nîmes, Nîmes, France.
- INSERM U1194, Montpellier University, Montpellier, France.
- CHU Nîmes, Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, Nîmes, France.
- UMR 1302, Desbrest Institute of Epidemiology and Public Health, INSERM, Montpellier University, Montpellier, France.
- Department of Urology, Georges Pompidou European Hospital, AP-HP Centre, Paris Cité University, Paris, France.
- Department of Medical Oncology, Georges Pompidou European Hospital, AP-HP, Paris Cité University, Paris, France.
ORCID-Profile: Nadine Houédé, François Audenet, Constance Thibault, Alexandra Masson-Lecomte, Gwenaëlle Gravis, Mathieu Roumiguié, Stéphane Droupy
Zitieren
APA
Houédé, N., Chevallier, T., Audenet, F., Thibault, C., Neuzillet, Y., Abraham, C., Masson-Lecomte, A., Gauthier, H., Gravis, G., Pignot, G., Tartas, S., Ruffion, A., Pouessel, D., Roumiguié, M., Laguerre, B., Bensalah, K., Xylinas, E., Jaffrelot, L., Droupy, S., …, & Rouprêt, M. (2025). Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00179
Vancouver
Houédé N, Chevallier T, Audenet F, Thibault C, Neuzillet Y, Abraham C, et al. Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial. Journal of Clinical Oncology. 2025. doi:10.1200/jco-25-00179
BibTeX
@article{Houd2025,
author = {Houédé, Nadine and Chevallier, Thierry and Audenet, François and Thibault, Constance and Neuzillet, Yann and Abraham, Christine and Masson-Lecomte, Alexandra and Gauthier, Hélène and Gravis, Gwenaëlle and Pignot, Géraldine and Tartas, Sophie and Ruffion, Alain and Pouessel, Damien and Roumiguié, Mathieu and Laguerre, Brigitte and Bensalah, Karim and Xylinas, Evanguelos and Jaffrelot, Loïc and Droupy, Stéphane and Luquiens, Guillaume and Rouprêt, Morgan},
title = {Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-25-00179}
}
EUVIMED